Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 282-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (NordCML006)

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 243-250

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 27-35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

By Signorovitch James E.   Wu Eric Q.   Betts Keith A.   Parikh Kejal   Kantor Evan   Guo Amy   Bollu Vamsi K.   Williams Denise   Wei L.J.   DeAngelo Daniel J.  

Current Medical Research and Opinion, Vol. 27, Iss. 6, 2011-06 ,pp. : 1263-1271

Informa Healthcare

Access to resources Recommend Favorite